Monogram Orthopaedics (NASDAQ:MGRM) Now Covered by Analysts at Roth Mkm

Roth Mkm began coverage on shares of Monogram Orthopaedics (NASDAQ:MGRM - Free Report) in a research report report published on Monday morning, Marketbeat.com reports. The firm issued a buy rating and a $4.00 target price on the stock.

Monogram Orthopaedics Stock Performance

Shares of MGRM traded up $0.21 during mid-day trading on Monday, reaching $2.46. The company had a trading volume of 107,727 shares, compared to its average volume of 143,465. The company has a market capitalization of $84.40 million, a price-to-earnings ratio of -5.23 and a beta of 2.01. The company's 50 day simple moving average is $2.26 and its 200 day simple moving average is $2.39. Monogram Orthopaedics has a 1-year low of $1.53 and a 1-year high of $4.90.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of MGRM. Barclays PLC acquired a new stake in shares of Monogram Orthopaedics during the 3rd quarter valued at $29,000. State Street Corp acquired a new stake in shares of Monogram Orthopaedics during the third quarter valued at about $62,000. Finally, Geode Capital Management LLC grew its holdings in shares of Monogram Orthopaedics by 1,267.4% during the third quarter. Geode Capital Management LLC now owns 210,144 shares of the company's stock worth $557,000 after purchasing an additional 194,776 shares during the last quarter. 0.45% of the stock is currently owned by institutional investors and hedge funds.

Monogram Orthopaedics Company Profile

Monogram Orthopaedics, Inc focuses on developing a product solution architecture to enable patient-optimized orthopaedic implants. The company intends to produce and market robotic surgical equipment and related software, orthopedic implants, tissue ablation tools, navigation consumables, and other miscellaneous instrumentation for use in reconstructive joint replacement procedures.